Fig 1: SRGN activates focal adhesion kinase through CD44.A-D Western blot analysis of phosphorylated FAK protein level in RAW264.7 cells after treatment with CM from GCTB-1 (A) or GCTB-19 (B) with SRGN knockdown, CM from hFOB1.19 with SRGN overexpression (C), or human recombinant SRGN protein (D). E Western blotting analysis of phosphorylated FAK protein level in RAW264.7 cells after treatment with CM from hFOB1.19 with SRGN overexpression and the CD44 neutralizing antibody. F Western blotting analysis of phosphorylated FAK in RAW264.7 cells after treatment with human recombinant SRGN protein and the CD44 neutralizing antibody. G, H Western blotting analysis of phosphorylated FAK in RAW264.7 CD44-knockout cells after treatment with CM from hFOB1.19 with SRGN overexpression (G) and human recombinant SRGN protein (H). I FAK phosphorylation levels in human GCTB samples with different levels of SRGN expression. Protein expression was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong) by immunohistochemistry staining (n = 71 patients). Scale bar, 100 µm. P values were obtained by chi-squared test (I).